Obesity & Heart Failure-Role of Tirzepatide

Obesity increases the risk of heart failure with preserved ejection fraction (HFpEF)

Obesity means increased adipocytes in the body which induces  systemic inflammation and particularly affect myocardium by changing epicardium adipose tissue proinflammatory. Increased plasma volume and inflammatory response results in HFpEF. Meaning risk of heart failure (especially with preserved ejection fraction) increases as body-mass index (BMI) increases.

Tirzepatide, glucose-dependent insulinotropic polypeptide GIP and glucagon-like peptide-1 receptors GLP-1 agonist, results in weight loss and useful in reducing obesity. Studies show that agonism of GLP-1 receptors reduces  proinflammatory nature of adipocytes, thus preventing them from causing fibrosis in the myocardium.

 Inaddition as GIP receptors are abundant in epicardial adipocytes its agonism suppresses inflammation in adjacent heart tissues. Tirzepatide regulates BP and HR and overall lowers the chance of heart failure. In addition to reducing body weight and the high-sensitivity CRP level, a measure of systemic inflammation, tirzepatide also improved health status and exercise tolerance, as measured by the 6-minute walk distance

Follow @mdresearch.us on Instagram & visit mdresearch.us for more insightful content and blogs!
#MedicalResearch #USResidency #BeUpToDateOnResearch #MedicalInsights #IMGs